UK Biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age by Sudlow, Cathie et al.
HEALTH IN ACTION
UK Biobank: An Open Access Resource for
Identifying the Causes of a Wide Range of
Complex Diseases of Middle and Old Age
Cathie Sudlow1,2, John Gallacher3, Naomi Allen2,4, Valerie Beral4, Paul Burton5,
John Danesh6, Paul Downey7, Paul Elliott7, Jane Green4, Martin Landray4, Bette Liu8,
Paul Matthews7, Giok Ong9, Jill Pell10, Alan Silman11, Alan Young4, Tim Sprosen4,
Tim Peakman2, Rory Collins2,4*
1 University of Edinburgh, Edinburgh, United Kingdom, 2 UK Biobank, Stockport, United Kingdom,
3 University of Cardiff, Cardiff, United Kingdom, 4 University of Oxford, Oxford, United Kingdom,
5 University of Bristol, Bristol, United Kingdom, 6 University of Cambridge, Cambridge, United Kingdom,
7 Imperial College, London, United Kingdom, 8 University of New South Wales, Sydney, Australia,
9 University of Warwick, Warwick, United Kingdom, 10 University of Glasgow, Glasgow, United Kingdom,
11 University of Manchester, Manchester, United Kingdom
* enquiries@ukbiobank.ac.uk
Summary Points
• UK Biobank is a very large and detailed prospective study with over 500,000 participants
aged 40–69 years when recruited in 2006–2010.
• The study has collected and continues to collect extensive phenotypic and genotypic de-
tail about its participants, including data from questionnaires, physical measures, sample
assays, accelerometry, multimodal imaging, genome-wide genotyping and longitudinal
follow-up for a wide range of health-related outcomes.
• Wide consultation; input from scientific, management, legal, and ethical partners; and
industrial-scale, centralised processes have been essential to the development of
this resource.
• UK Biobank is available for open access, without the need for collaboration, to any bona
fide researcher who wishes to use it to conduct health-related research for the benefit of
the public.
The challenge of understanding the determinants of common life-threatening and disabling
conditions is substantial. These conditions are typically caused by a combination of lifestyle,
environmental, and genomic factors, with individually modest effects and complex interac-
tions, the detection and quantification of which require studies with large numbers of disease
cases. While retrospective case-control studies of particular diseases [1] or existing prospective
studies of particular risk factors can help to address this challenge [2,3], a complementary ap-
proach is to establish large prospective cohorts designed to study a much wider range of known
and novel risk factors for a wide range of diseases [4]. Prospective studies can assess exposures
before the onset and treatment of disease, diseases that are not readily investigated by
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retrospective studies, and both the adverse and beneficial effects of a specific exposure on the
lifetime risks of different diseases.
UK (United Kingdom) Biobank is a very large, population-based prospective study, estab-
lished to allow detailed investigations of the genetic and nongenetic determinants of the dis-
eases of middle and old age [5,6]. It aims to combine extensive and precise assessment of
exposures with comprehensive follow-up and characterisation of many different health-related
outcomes, as well as to promote innovative science by maximising access to the resource. Re-
cruitment of 500,000 participants and the collection of an unprecedented wealth of baseline
data and samples were completed in 2010. Activity is now focused on further phenotyping of
participants and their health outcomes and on providing access to researchers from around
the world.
Cohort Size
The large size of the cohort was based on statistical power calculations for nested case-control
studies [7], showing that 5,000–10,000 cases of any particular condition would be required for
the reliable detection of odds ratios (ORs) for the main effects of different exposures of 1.3–1.5
(the upper end of the range reported from genome-wide association studies of various condi-
tions [8]), and around 20,000 cases for detection of interactions with ORs of at least 2.0. To ob-
serve such large numbers of cases of particular diseases within a reasonable follow-up period,
prospective cohorts need very large numbers of participants. Projected numbers of cases of a
range of common conditions expected to occur among 500,000 UK Biobank participants dur-
ing 20 years of follow-up (Table 1) suggest that reliable assessment of the main determinants of
most of these conditions (and others that are similarly common) should be possible during the
current decade [6,9]. The age range for inclusion of 40–69 years represented a pragmatic com-
promise between participants being old enough for there to be sufficient incident health out-
comes during the early years of follow-up and young enough for the initial assessment to occur
before incipient disease had a material impact on exposures.
Table 1. Approximate numbers of incident cases of some exemplar conditions expected to accrue during the ﬁrst 20 years of follow-up in UK
Biobank.
Condition 2012 2017 2022 2027
Diabetes mellitus 10,000 25,000 40,000 68,000
MI and coronary death 7,000 17,000 28,000 47,000
Stroke 2,000 5,000 9,000 20,000
COPD 3,000 8,000 14,000 25,000
Breast cancer (female) 2,500 6,000 10,000 16,000
Colorectal cancer 1,500 3,500 7,000 14,000
Prostate cancer 1,500 3,500 7,000 14,000
Lung cancer 800 2,000 4,000 8,000
Hip fracture 800 2,500 6,000 17,000
Rheumatoid arthritis 800 2,000 3,000 5,000
Alzheimer’s disease 800 3,000 9,000 30,000
Parkinson’s disease 1000 3,000 6,000 14,000
Based on UK age- and sex-speciﬁc rates with adjustment for healthy cohort effects and losses to follow-up [6].
MI: myocardial infarction; COPD: chronic obstructive pulmonary disease or chronic bronchitis/emphysema
doi:10.1371/journal.pmed.1001779.t001
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Data Availability
Data from the Baseline Assessment
The 500,000 participants were assessed between 2006 and 2010 in 22 assessment centres
throughout the UK, covering a variety of different settings to provide socioeconomic and ethnic
heterogeneity and urban–rural mix. This ensured a broad distribution across all exposures to
allow the reliable detection of generalisable associations between baseline characteristics and
health outcomes. The assessment visit comprised electronic signed consent; a self-completed
touch-screen questionnaire; brief computer-assisted interview; physical and functional measures;
and collection of blood, urine, and saliva (Table 2). Multiple aliquots of different sample fractions
are stored in UK Biobank’s automated laboratory, allowing for a wide range of future assays [10].
Data from Additional Assessments to Enhance Phenotyping
UK Biobank is conducting a range of additional phenotyping assessments in all (or large subsets)
of the participants. Data are already available both from a detailed dietary web questionnaire
[11], completed up to four times by over 200,000 participants, and from the first repeat of the en-
tire baseline assessment in around 20,000 participants [12]. Over the coming months and years,
further data will become available from: a range of biochemical assays and genome-wide geno-
typing of baseline samples from all participants; Web-based questionnaires to assess specific
characteristics in more detail (e.g., cognitive function, occupational history); and, in subsets of
100,000 participants, collection of data from physical activity monitors and multi-modal imaging
(Table 3).
Data from Longitudinal Follow-Up for Health-Related Outcomes
Follow-up is conducted chiefly through linkages to routinely available national datasets. Data
are already available on over 8,500 deaths, over 75,000 prevalent and incident cancers, and
over 600,000 hospital admissions, while linkages are planned to a range of other datasets, in-
cluding primary care, cancer screening data, and disease-specific registers. In addition, to re-
duce misclassification and increase biological specificity of health outcomes, UK Biobank is
developing methods for accurate identification and detailed phenotyping of outcomes in a
range of disease areas. Initial ascertainment of outcomes with electronic and semi-automated
sources will be supplemented by more intensive methods (e.g., retrieval of case records, imag-
ing data, or banked tissue samples) for validation and subclassification (Table 3).
Online Open Access to Researchers
Many cohort studies have mechanisms for sharing data with external researchers on a collabo-
rative basis, but relatively few have arrangements for open access to the data without any need
for collaboration, and even fewer have been established from the outset with the intention of
making the entire resource available to the global research community. The development of
open access arrangements for data from cohort studies is an important step in maximising
their impact with respect to scientific publications, policy making, and understanding of health
and disease. Examples of resources whose impact has been enhanced in this way include the
UK 1958 birth cohort study [13] and the Australian 45 and Up cohort study [14].
UK Biobank aims to encourage and provide as wide access as possible to its data and sam-
ples for health-related research in the public interest by all bona fide researchers from the aca-
demic, charity, public, and commercial sectors, both in the UK and internationally, without
preferential or exclusive access for any user. UK Biobank’s publicly available Data Showcase
(http://www.ukbiobank.ac.uk/) presents the univariate distributions and methods used for
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collection of all the variables available for health-related research, enabling potential research
users to explore what data are available and plan research applications.
An online access process, launched in April 2012, aims to be fair, transparent, and stream-
lined. Applications for data only are approved so long as the proposed research is in the public
interest and the data required are, or will become, available. Applications involving the use of
depletable samples or requiring participant re-contact are subject to a more rigorous process of
scrutiny and scientific review. Following initial assessment by the executive team, all applica-
tions are assessed and either approved or rejected (with right of appeal) by an independent Ac-
cess Subcommittee. Advice is sought on any applications raising potential ethical issues from
both the University of Oxford’s Ethox Centre and the Ethics and Governance Council. Only
de-identified data are provided to researchers, who must sign a material transfer agreement,
undertaking not to attempt to identify any participant, to keep the data secure, and to use it
only for the purposes of the approved research. Researchers must also undertake to publish
their results and to return details of their methods, derived data, and/or sample assay results
for incorporation into the UK Biobank dataset so that they can be made available to other ap-
proved researchers (see www.ukbiobank.ac.uk/scientists/ for details). UK Biobank encourages,
but does not mandate, publication of results of research based on the resource in open access
journals. Ensuring that the resource and its access arrangements are widely communicated is
an important task, requiring a dedicated communications team to manage UK Biobank’s
Table 2. Data collected at the baseline assessment.
Questionnaire and interview
Sociodemographic Social class; ethnicity; employment status; marital status; education; income; car ownership
Family history and early life exposures Family history of major diseases; birth weight; breast feeding; maternal smoking; childhood body size;
residence at birth
Psychosocial factors Neurosis; depression (including bi-polar spectrum disorder); social support
Environmental factors Current address; current (or last) occupation; domestic heating and cooking fuel; housing; means of travel;
shift work; mobile phone use; sun exposure
Lifestyle Smoking; alcohol consumption; physical activity; diet; sleep
Health status Medical history; medications; disability; hearing; sight; sexual and reproductive history
Hearing threshold Speech reception threshold*
Cognitive function Pairs matching; reaction time; prospective memory*; ﬂuid intelligence*; numeric memory†
Physical measures
Blood pressure and heart rate two automated measures, one minute apart
Grip strength Left- and right-hand grip strength
Anthropometrics Standing and sitting height; weight and bio-impedance; hip and waist circumference
Spirometry Up to three measures
Bone density‡ Calcaneal ultrasound
Arterial stiffness¶ Pulse wave velocity
Eye examination§ Refractive index, intraocular pressure; acuity; retinal photograph; optical coherence tomography
Fitness test§ Cycle ergometry with electrocardiogram (ECG) heart rate monitoring
* assessed in 170,000 participants;
† assessed in 50,000 participants;
‡measured in one heel for 170,000 participants and in both heels for 320,000 participants;
¶ measured in 170,000 participants;
§ measured in 100,000 participants
doi:10.1371/journal.pmed.1001779.t002
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Table 3. Current and planned future data available in the UK Biobank resource.
Data type Number of
participants
Details Date of data
acquisition
Date ﬁrst
available for
research‡
Baseline assessment Whole cohort Questionnaire, physical measures, samples (see Table 2);
haematological assays done on fresh blood samples
2006–2010 Q2 2012
Repeat of baseline
assessment
20,000–25,000 As above every few years, to allow correction for regression
dilution due to measurement error and within person
ﬂuctuations in exposure levels [12].
2013– Q3 2013
Biochemical assays
(of baseline samples)
Whole cohort Biomarkers with known disease associations (e.g., lipids for
vascular disease), diagnostic value (e.g., HbA1c for
diabetes), or ability to characterize phenotypes not
otherwise well assessed (e.g., renal and liver function tests).
2014–2015 2015
Genotyping (of
baseline samples)
Whole cohort Dense genotyping chip with >800,000 markers including:
approximately 250,000 SNPs in a whole-genome array;
approximately 200,000 markers covering CNV, loss of
function, insertions, deletions, and previously identiﬁed risk
factor or disease associations; approximately 150,000
exome markers covering a high proportion of non-
synonymous coding variants with allele frequency >0.02%.
2013–2015 2015
Dietary Web
questionnaire
210,000 Automatically coded dietary recall questionnaire, providing
estimates of nutrient intake. 80,000 respondents completed
it  three times.
2011–2012 Q2 2013
Other Web
questionnaires
350,000 to be
approached
Participants invited by email to provide additional
information via Web questionnaires about exposures (e.g.,
occupation) and health outcomes (cognitive function,
depression) that are not readily identiﬁed from health record
linkages.
2014– 2015
Accelerometry 100,000 Wrist-worn tri-axial accelerometers record information on
type, intensity, and duration of physical activity.
2013–2015 2015
Multimodal imaging 100,000 MRI brain, heart, and abdomen (for lipid distribution);
ultrasound of carotid arteries; whole body DXA scan of
bones and joints
Pilot phase: 2014–
2015 Main phase:
2016–2019
2015
Health record linkage Whole cohort
Death registrations ICD-coded cause speciﬁc mortality 2006– Q2 2013
Cancer registrations ICD-coded cancer diagnoses 1971–* Q2 2013
Hospital inpatient episodes ICD-coded diagnoses, OPCS-coded procedures 1997–* Q4 2013
Hospital outpatient episodes Limited ICD and OPCS coding 2003–* 2015
Primary care Read-coded information including diagnoses,
measurements, referrals, prescriptions
Variable 2015
Other UK Biobank will obtain data from national mental health
care, residential history, laboratory and disease audit
datasets and is considering the value of further linkages (e.
g., imaging, cancer screening, dental).
Variable Not yet
determined
Adjudicated health
outcomes
Whole cohort Expert-led conﬁrmation and subclassiﬁcation of outcomes in
a range of disease areas, including cancer, diabetes, heart
disease, stroke, mental health, musculoskeletal, respiratory,
neurodegenerative, and ocular disorders.
2015
Hb: haemoglobin; SNPs: single nucleotide polymorphisms; CNV: copy number variations; MRI: magnetic resonance imaging; DXA: dual-energy X-ray
absorptiometry; ICD: International Classiﬁcation of Diseases; OPCS: Ofﬁce of Population Censuses and Surveys Classiﬁcation of Interventions and
Procedures
‡ Future dates are estimated. Data available may be all or part of the relevant dataset.
* available from an earlier date from health record systems in Scotland
doi:10.1371/journal.pmed.1001779.t003
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website, scientific meetings, and other methods for communication with the scientific commu-
nity, including emails, newsletters, and other social media. In the first two years after the
launch of open access to UK Biobank, over 1,000 researchers successfully registered, and over
200 applications were submitted (see www.ukbiobank.ac.uk/approved-research/ for a summary
of research that is currently underway). Over 80% of registered researchers were from the UK
and over 95% from academic rather than commercial institutions. Approximately 85% of ap-
plications were for data only, with few as yet requesting use of samples or participant re-
contact. UK Biobank has now started to receive notifications of submitted abstracts and
manuscripts based on the first few completed research projects. UK Biobank reviews its
access procedures regularly, revising them in the light of experience and user feedback to
make the process as streamlined as possible while remaining consistent with
participant consent.
Running UK Biobank
Success so far in developing and enhancing the resource has relied on public willingness to par-
ticipate in prospective research studies; close engagement with funders, government health de-
partments, and the UK National Health Service; extensive consultation with the public,
scientists, and a wide range of regulatory, legal, and ethics bodies; and the development of cost-
effective and efficient methodological approaches. The most significant challenges to be over-
come are the implementation of scientifically rigorous processes on a very large scale, sustain-
ing the funding required to ensure the benefits of the resource are fully realised, obtaining
approvals from multiple regulatory bodies in a frequently changing political and healthcare en-
vironment, and ensuring as wide as possible communication of the non-preferential, open ac-
cess nature of the resource.
Interactions with Participants
Participant recruitment, retention, and engagement with enhancement projects has benefited
from the willingness of very large numbers of British people to take part in observational re-
search without the prospect of direct personal gain [15]. Participants spent an average of about
two and a half hours at the recruitment visit. All gave broad consent to use of their anonymised
data and samples for any health-related research, to be re-contacted for further substudies, and
for UK Biobank to access their health-related records. Large subsets have subsequently com-
pleted Web-based questionnaires, agreed to wear a physical activity monitor, and repeated the
entire baseline assessment. Of those who attended the first repeat assessment visit and provided
feedback, 92% reported that they would be willing to travel for up to two hours for an imaging
assessment visit lasting half a day. UK Biobank keeps its participants involved through provid-
ing progress updates via its website, with annual newsletters, and through its dedicated Partici-
pant Resource Centre (PRC), enabling them to continue to support the project and participate
in research over the years ahead.
Interactions with Funding Bodies
Having established UK Biobank as a charitable company over a decade ago, the UKMedical
Research Council and Wellcome Trust have provided the vast majority of its funding so far.
These major funders have had the long-term vision to continue to invest substantially in its on-
going development as a global research resource, coordinating both the scientific review of
major proposals for developments to the resource and contributions from other funding bod-
ies, including the Department of Health, Scottish andWelsh Governments, North West Devel-
opment Agency, British Heart Foundation, and Diabetes UK. Long-term funding is not
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guaranteed, but depends on UK Biobank working in close partnership with its funders towards
the common goal of facilitating high-quality, cost-effective research that will improve the pub-
lic’s health. Crucial to this partnership is provision and joint discussion of regular updates on
progress against challenging milestones, new strategic goals, scientific opportunities, financial
plans, and use of the resource to generate new scientific knowledge.
Interactions with the UK’s Publicly Funded National Health Service
Participant recruitment relied on invitations being mailed to 9 million people whose contact
details were obtained from National Health Service (NHS) central registers. Large-scale epide-
miological studies in the UK benefit from the fact that 98% of the population is registered with
the NHS, which keeps detailed records on all of them from birth to death. Linkages to NHS
datasets provide the principal means of follow-up for health-related outcomes.
Industrial Scale, Centralised Processes
A key step in achieving the cost-effective recruitment, characterisation, and follow-up of
500,000 participants was the creation of an executive and advisory team with complementary
scientific and management skills and a coordinating centre dedicated to the generation of a re-
source for the scientific community. This facilitated the development of a centralised infra-
structure, bespoke information technology (IT) systems, and industrial approaches to
collection and processing of data and samples. For example, inviting potential participants via
individual general-practice groupings (an approach used by smaller UK population-based
studies) would have been impractical for a study of UK Biobank’s scale, so appropriate approv-
als were obtained to allow direct mailing of invitations using contact details held centrally by
the NHS. The recruitment process itself was coordinated centrally, with up to six assessment
centres being active at any one time during the recruitment phase. Staffing and equipment
needs were carefully configured to ensure the smooth flow of around 100 participants per day
through each assessment centre for six days per week. Biological samples were also processed
and handled centrally, requiring the development of bespoke laboratory information manage-
ment and automated robotic systems to facilitate rapid, error-free sample storage in, and ex-
traction from, the freezers (at rates of up to 1,500 samples per day) according to particular
sample and participant characteristics [16]. Each step of the recruitment, assessment, and sam-
ple handling process was first piloted, modified as necessary and monitored centrally, using
statistical methods to identify potential performance issues. Similar industrial-scale, centralised
processes have been or are being developed for the repeat assessment and imaging visits.
Governance Structure
UK Biobank’s Board of Directors has overall responsibility for its direction and management.
An Executive Management Team, with epidemiology, clinical, management, laboratory, legal,
and communications expertise, oversees the development and day-to-day management of the
resource and is responsible for the staff working on the study, most of them based at its coordi-
nating centre near Manchester, with others at the Universities of Oxford, Edinburgh, Cardiff,
and London. The executive team receives guidance from a Steering Committee of leading UK
scientists, supported by specialist working groups advising on baseline data collection, en-
hanced phenotyping, follow-up and outcomes adjudication, and an international perspective is
provided by an International Scientific Advisory Board (see S1 Consent Form and www.
ukbiobank.ac.uk/governance/). This governance structure has facilitated effective working be-
tween scientific and management disciplines, allowing UK Biobank to respond to advice from
a wide network of scientists on the most scientifically valuable design and development of the
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resource, with project management and implementation being the responsibility of UK Bio-
bank’s Executive Management Team and dedicated staff.
Robust Ethics and Governance Framework
UK Biobank has consulted widely not only with the scientific community but also with the
public, its participants, and other interested parties [17,18]. This has informed the development
of its Ethics and Governance Framework, which lays out its principles and policies [19], as well
as its access procedures [20]. UK Biobank’s research ethics committee and Human Tissue Au-
thority research tissue bank approvals mean that researchers wishing to use the resource do
not need separate ethics approval (unless re-contact with participants is required). An indepen-
dent Ethics and Governance Council oversees adherence to the Ethics and Governance Frame-
work and provides advice on the interests of research participants and the general public in
relation to UK Biobank.
In keeping with the informed consent given by its participants, UK Biobank does not gener-
ally provide feedback to individual participants about information derived from analyses of
data or samples made following their assessment visits. Participants receive limited individual
feedback in two areas. First, they receive a summary of standard measures (e.g., blood pressure,
body mass index) at the end of each assessment visit and are encouraged to seek medical advice
for results outside the normal range. Second, potentially serious incidental findings (i.e., those
likely to threaten life span or have a major impact on quality of life) observed by study staff
during these assessments (e.g., possible melanoma on exposed areas of skin) are brought to the
attention of participants with encouragement to contact a relevant health professional. Similar
feedback is occurring in the imaging substudy, with participants and their general practitioners
informed of potentially serious incidental findings noticed by radiographers and confirmed by
formal radiologist review. In addition, the overall findings and implications of results that de-
rive from research using the UK Biobank resource are made available to researchers, partici-
pants, and the wider community so that they can influence public health strategies.
Interactions with Regulatory Bodies
The wide consultation, rigorous Ethics and Governance Framework, and Ethics and Gover-
nance Council oversight role have been essential in paving the way for UK Biobank to accom-
plish obtaining the multiple ethical and regulatory approvals required for participant
recruitment, sample and data storage, linkages to routine health care data, enhancement stud-
ies, and the provision of access to data and samples for approved researchers. Substantial
amounts of time, resources, patience, tenacity, and evidence of feasibility and/or acceptability
from smaller scale pilot studies have also been required to provide regulatory bodies with the
reassurance that they need of UK Biobank’s rigorous approach and commitment to protecting
the interests of its participants within an acceptable legal and ethical framework.
Conclusions
The key lessons learned from establishing UK Biobank are that such large-scale studies require
not only a clear scientific focus but also streamlined governance; effective working between ac-
ademic and management disciplines; centralised infrastructure with industrial approaches to
collection and processing of data and samples; close partnership with major funders; a wide
network of scientific advisors; high-quality, pragmatic legal and ethical advice; and widespread
public support [21]. The resource is now facilitating research by scientists from around the
world who wish to investigate how different diseases are caused by the combination of lifestyle,
environment, and genes, leading to improvements in prevention, diagnosis, and treatment.
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Perhaps unsurprisingly, early use has been mainly, but not exclusively, by UK-based scientists.
A major aim for the immediate future is to encourage applications from outside the UK. To fa-
cilitate this, UK Biobank is further developing its communications strategy to increase aware-
ness of the resource and its access procedures worldwide.
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